Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

Basit Öğe Kaydı
dc.authorid0000-0003-2715-4002
dc.authorid0000-0003-0128-6947
dc.contributor.authorKutlu, Yasin
dc.contributor.authorÇekin, Ruhper
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorShbair, Abdallah T. M.
dc.contributor.authorBilici, Ahmet
dc.contributor.authorArıcı, Serdar
dc.contributor.authorÖven, Bala Başak
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorÖzcan, Erkan
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorÇakır, Aslı
dc.contributor.authorŞeker, Mesut
dc.date.accessioned2024-06-05T07:34:54Z
dc.date.available2024-06-05T07:34:54Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractLoss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. We aimed to investigate the importance of HER2 loss, additionally with predictive factors for the loss of HER2. This was a retrospective and multicenter study that included 272 HER2-positive BC patients with no pathological complete response who received neoadjuvant chemotherapy plus HER2-targeted treatments. The factors that may affect the loss of HER2 detected by immunohistochemistry(IHC) and the association with survival were analyzed.The rate of HER2 loss after neoadjuvant treatments(NAT) was 27.9 % (n = 76). Disease recurrence was observed in 18(23.7 %) patients with HER2 loss, while it was detected in 62 (31.7 %) patients without HER2 loss(p = 0.23). Pre and post-NAT ER status, and post-NAT ki-67 status had a significant impact on disease-free survival(DFS) (p = 0.0012, p = 0.004, and p = 0.04, respectively).There were no significant association between DFS and loss of HER2 (p = 0.64) and dual anti-HER2 blockade (p = 0.21). Pre-NAT clinical stage (HR:1.65 p = 0.013), post-NAT LN status (HR:3.18, p = 0.02) and pre-NAT ER status (HR:0.24, p = 0.041) were significant independent prognostic factors for DFS while post-NAT residual disease in axillar tissue was an independent prognostic factor for OS (HR:1.54 p = 0.019). Moreover, age (<40 years vs ?40 years) (p = 0.031) and tumor grade (p = 0.004) were predictive factors for HER2 loss. Our results showed that HER2 loss did not affect survivals. However, young age and being high grade tumor may predict HER2 loss.
dc.identifier.citationKutlu, Y., Çekin, R., Göktaş Aydın, S., Shbair, A. T. M., Bilici, A., Arıcı, S. ... Şeker, M. (2024). Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer. Current Problems in Cancer, 50. http://dx.doi.org/10.1016/j.currproblcancer.2024.101102
dc.identifier.doi10.1016/j.currproblcancer.2024.101102
dc.identifier.issn0147-0272
dc.identifier.issn1535-6345
dc.identifier.pmid38735211
dc.identifier.scopus2-s2.0-85193027238
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1016/j.currproblcancer.2024.101102
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12567
dc.identifier.volume50
dc.identifier.wos001242968000001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKutlu, Yasin
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet
dc.institutionauthorAçıkgöz, Özgür
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorÇakır, Aslı
dc.language.isoen
dc.relation.ispartofCurrent Problems in Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBreast Cancer
dc.subjectDisease-Free Survival
dc.subjectHER2 Expression Loss
dc.subjectNeoadjuvant Treatment
dc.titlePrognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kutlu-Yasin-2024.pdf
Boyut:
678.26 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu